AU2016359907B2 - Heterocyclic indoles for use in influenza virus infection - Google Patents

Heterocyclic indoles for use in influenza virus infection Download PDF

Info

Publication number
AU2016359907B2
AU2016359907B2 AU2016359907A AU2016359907A AU2016359907B2 AU 2016359907 B2 AU2016359907 B2 AU 2016359907B2 AU 2016359907 A AU2016359907 A AU 2016359907A AU 2016359907 A AU2016359907 A AU 2016359907A AU 2016359907 B2 AU2016359907 B2 AU 2016359907B2
Authority
AU
Australia
Prior art keywords
mmol
influenza
compound
pharmaceutically acceptable
stereo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016359907A
Other languages
English (en)
Other versions
AU2016359907A1 (en
Inventor
Wendy Mia Albert Balemans
Christophe Francis Robert Nestor Buyck
Ludwig Paul Cooymans
Werner Constant Johan Embrechts
Jérôme Emile Georges GUILLEMONT
Tim Hugo Maria Jonckers
David Craig Mc Gowan
Pierre Jean-Marie Bernard Raboisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of AU2016359907A1 publication Critical patent/AU2016359907A1/en
Application granted granted Critical
Publication of AU2016359907B2 publication Critical patent/AU2016359907B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016359907A 2015-11-27 2016-11-25 Heterocyclic indoles for use in influenza virus infection Ceased AU2016359907B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196811 2015-11-27
EP15196811.2 2015-11-27
PCT/EP2016/078778 WO2017089518A1 (en) 2015-11-27 2016-11-25 Heterocyclic indoles for use in influenza virus infection

Publications (2)

Publication Number Publication Date
AU2016359907A1 AU2016359907A1 (en) 2018-05-24
AU2016359907B2 true AU2016359907B2 (en) 2021-04-01

Family

ID=54707665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016359907A Ceased AU2016359907B2 (en) 2015-11-27 2016-11-25 Heterocyclic indoles for use in influenza virus infection

Country Status (16)

Country Link
US (1) US10626108B2 (cg-RX-API-DMAC10.html)
EP (1) EP3380467B1 (cg-RX-API-DMAC10.html)
JP (1) JP6903658B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180087290A (cg-RX-API-DMAC10.html)
CN (1) CN108290869B (cg-RX-API-DMAC10.html)
AU (1) AU2016359907B2 (cg-RX-API-DMAC10.html)
CA (1) CA3005514A1 (cg-RX-API-DMAC10.html)
DK (1) DK3380467T3 (cg-RX-API-DMAC10.html)
EA (1) EA201891278A1 (cg-RX-API-DMAC10.html)
ES (1) ES2882671T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211223T1 (cg-RX-API-DMAC10.html)
HU (1) HUE055200T2 (cg-RX-API-DMAC10.html)
LT (1) LT3380467T (cg-RX-API-DMAC10.html)
MA (1) MA43298A (cg-RX-API-DMAC10.html)
SI (1) SI3380467T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017089518A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
BR112018014794A2 (pt) * 2016-01-20 2018-12-11 Janssen Sciences Ireland Uc pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
CN107759571B (zh) 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
CA3045371C (en) 2016-12-15 2024-05-14 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
EP4306166A3 (en) * 2016-12-23 2024-06-26 Aquinnah Pharmaceuticals Inc. Compounds, compositions and methods of use
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083122A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801971A (zh) 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
EP2040546A4 (en) * 2006-06-22 2009-12-23 Merck & Co Inc tyrosine kinase inhibitor
RU2481340C2 (ru) 2007-02-08 2013-05-10 Тиботек Фармасьютикалз Лтд. Пиримидин-замещенные макроциклические ингибиторы hcv
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
ES2691745T3 (es) 2011-04-08 2018-11-28 Janssen Sciences Ireland Uc Derivados de pirimidina para el tratamiento de infecciones víricas
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2013334001B2 (en) 2012-10-16 2017-07-20 Janssen Sciences Ireland Uc RSV antiviral compounds
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
BR112018014794A2 (pt) 2016-01-20 2018-12-11 Janssen Sciences Ireland Uc pirimidinas substituídas com arila para uso em infecção pelo vírus influenza

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083122A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL P. CLARK ET AL, "Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2", JOURNAL OF MEDICINAL CHEMISTRY, US, (2014-07-14), vol. 57, no. 15, pages 6668 - 6678 *

Also Published As

Publication number Publication date
ES2882671T3 (es) 2021-12-02
CN108290869A (zh) 2018-07-17
WO2017089518A1 (en) 2017-06-01
JP2019501879A (ja) 2019-01-24
HRP20211223T1 (hr) 2021-11-12
EP3380467A1 (en) 2018-10-03
US10626108B2 (en) 2020-04-21
CN108290869B (zh) 2021-05-18
CA3005514A1 (en) 2017-06-01
DK3380467T3 (da) 2021-09-27
AU2016359907A1 (en) 2018-05-24
US20180258074A1 (en) 2018-09-13
KR20180087290A (ko) 2018-08-01
LT3380467T (lt) 2021-08-10
EA201891278A1 (ru) 2018-11-30
SI3380467T1 (sl) 2021-08-31
MA43298A (fr) 2021-04-14
EP3380467B1 (en) 2021-07-07
JP6903658B2 (ja) 2021-07-14
HUE055200T2 (hu) 2021-11-29

Similar Documents

Publication Publication Date Title
EP3380467B1 (en) Heterocyclic indoles for use in influenza virus infection
AU2017209925B2 (en) Aryl substituted pyrimidines for use in influenza virus infection
EP3191489B1 (en) Pyrrolopyrimidines for use in influenza virus infection
AU2015298876B2 (en) Indoles for use in influenza virus infection
AU2017205261B2 (en) Functionalized pentanoic acids for use in influenza viral infections
HK40000702A (en) Aryl substituted pyrimidines for use in influenza virus infection
HK40000702B (en) Aryl substituted pyrimidines for use in influenza virus infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired